Evidence map›Paper›PMID 25806852›Full record

ArticleThe Journal of investigative dermatology2015

Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.

Henry K Wong, Heather Gibson, Timothy Hake, Susan Geyer, Julie Frederickson, Guido Marcucci, Michael A Caligiuri, Pierluigi Porcu, Anjali Mishra

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Epigenetics of Cutaneous T-Cell Lymphomas.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Cutaneous T cell lymphoma.Nature reviews. Disease primers · 2021
    Review
  8. Plastin 3 in health and disease: a matter of balance.Cellular and molecular life sciences : CMLS · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Henry K WongDivision of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA. Electronic address: hkwong@uams.edu.
Heather GibsonDivision of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; These authors contributed equally to this work.
Timothy HakeDivision of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Susan GeyerThe Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Julie FredericksonDivision of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Guido MarcucciThe Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA.
Michael A CaligiuriThe Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA.
Pierluigi PorcuThe Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA. Electronic address: Pierluigi.Porcu@osumc.edu.
Anjali MishraDivision of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA. Electronic address: Anjali.Mishra@osumc.edu.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · US

Funding

Novel Biomarkers in Cutaneous T Cell LymphomaR21CA164911 · NCI · OHIO STATE UNIVERSITY · PI PORCU, PIERLUIGI, WONG, HENRY KEUNG · 2012 to 2013
$355k
Gene expression abnormalities in mycosis fungoidesR21AR052877 · NIAMS · HENRY FORD HEALTH SYSTEM · PI WONG, HENRY KEUNG · 2006 to 2007
$345k
NCI NIH HHS R21 CA164911NIAMS NIH HHS R21 AR052877
6 · The paper itself

Abstract

The Sézary Syndrome (SS) is an aggressive CD4+ leukemic variant of cutaneous T-cell lymphoma. Epigenetic modification of cancer cell genome is often linked to the expression of important cancer-related genes. Here we addressed the hypothesis that, in SS, DNA hypomethylation is involved in upregulation of PLS3, GATA6, and TWIST1, genes that are undetected in normal lymphocytes. Pyrosequencing analysis of CpG rich regions, and CpG dinucleotides within the 5' regulatory regions, confirmed hypomethylation of all three genes in SS, compared with controls. We then studied how methylation regulates PLS3 transcription in vitro using PLS3-negative (Jurkat) and PLS3-positive (HT-1080) cell lines. Treatment with the hypomethylating agent 5-azacytidine induced PLS3 expression in Jurkat cells and in vitro methylation of the cloned PLS3 promoter suppressed luciferase expression in HT-1080 cells. In conclusion, we show that promoter hypomethylation is associated with PLS3, GATA6, and TWIST1 overexpression in SS CD4+ T cells and that methylation can regulate PLS3 expression in vitro. The mechanisms of DNA hypomethylation in vivo and the functional role of PLS3, TWIST1, and GATA6 in SS are being investigated.

Indexed as

AgedAzacitidineCase-Control StudiesCell LineDNA MethylationFemaleFibroblastsGATA6 Transcription FactorGene Expression Regulation, NeoplasticHumansIn Vitro TechniquesJurkat CellsLymphocytesMaleMembrane GlycoproteinsMicrofilament ProteinsAzacitidineGATA6 protein, humanGATA6 Transcription FactorMembrane GlycoproteinsMicrofilament ProteinsNuclear ProteinsplastinRNA, MessengerTWIST1 protein, humanTwist-Related Protein 1

Identifiers

PMID25806852
OpenAlexW2093918575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.